Showing 1391-1400 of 7578 results for "".
A Biologic Test for Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/a-biologic-test-for-cutaneous-squamous-cell-carcinoma/24025/Cutaneous squamous cell carcinoma (cSCC) encompasses a broad spectrum of disease severity, from superficial and easily treatable skin lesions to potentially life-threatening metastatic cancer. Adjuvant radiation therapy (ART) is recommended to reduce the likelihood of relapse following surgical reseCutaneous Toxicities in Graft-versus-host Disease
https://practicaldermatology.com/conferences/masterclasses-in-dermatology-2025/cutaneous-toxicities-in-graft-versus-host-disease/33013/Meghan Heberton, MD, an assistant professor of dermatology at UT Southwestern Medical Center, talks about her presentation at Masterclasses in Dermatology on the latest updates on cutaneous toxicities in Graft-versus-host (GvHD) disease.Cannabinoid Photo-Rejuvenation: A Clinico-Pathologic Study
https://practicaldermatology.com/topics/feature/cannabinoid-photo-rejuvenation-a-clinico-pathologic-study/29188/In this study, we sought to assess the effectiveness of a novel topical formulation containing CBD isolate, resveratrol, thyme extract, caffeine, and lecithin in reversing photodamage over a 90-day treatment period.Embrace Your Curiosity: The Power of Questions
https://practicaldermatology.com/topics/practice-management/embrace-your-curiosity-the-power-of-questions/24031/Asking empowering questions may yield more creative answers.How Early Experience With PDT Can Provide Career Pathways
https://practicaldermatology.com/series/pdt-in-practice/how-early-experience-with-pdt-can-provide-career-pathways/20212/Adam Friedman, MD, professor and chair of dermatology at George Washington University, discusses how early-career experience with photodynamic therapy, including exposure to doctor-mentors in the field, gave him professional skills and connections that prepared him for later-career opportunities.PDT: Patient Profiles for a Practice-changing Treatment
https://practicaldermatology.com/series/pdt-in-practice/pdt-patient-profiles-for-a-practice-changing-treatment/20186/Who's the ideal candidate for PDT? Other options, limitations? The advances in PDT both doctors and patients would like to see are described by Corey Hartman, MD, who shares his experiences and relates how PDT has improved his practice.Oh, What a Year!
https://practicaldermatology.com/columns/clinical-focus-1/oh-what-a-year/23840/Practical Dermatology’s Clinical Focus Editors recall the greatest breakthroughs in acne, rosacea, psoriasis, and atopic dermatitis of 2022Tips for Success with Fillers
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/tips-for-success-with-fillers/20149/Heidi Waldorf, MD offers tips for getting the best results possible with fillers. From how to evaluate what patients need to considering shapes and proportions, she offers hands-on advice to help achieve optimal outcomes. Plus, she discusses the importance of managing patient expectations.Landing in Dermatology
https://practicaldermatology.com/series/scientifically-speaking/landing-in-dermatology/20129/Humberto Antunes talks to host Joel L. Cohen, MD about how he got his start in dermatology and why the field appealed to him.DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent e